Adjuvant chemotherapy for anaplastic gliomas
US6653351B2 · kind B2 · utility
3Cited by
13References
33Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 13, 2002 |
| Grant date | Nov 25, 2003 |
| Priority date | — |
| Expiry date | Aug 13, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a combination therapy using eflomithine (DFMO) and PCV (matulane, lomustine and vincristine) in the treatment of anaplastic gliomas. In contrast to the results seen with glioblastoma multiforme, anaplastic gliomas responded better to the combination of DFMO and PCV than to either the PCV combination or DFMO alone, extending patient survival by approximately two years.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.